Search our Database of Scientific Publications and Authors

I’m looking for a

    14431 results match your criteria Annals of the Rheumatic Diseases[Journal]

    1 OF 289

    Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
    Ann Rheum Dis 2018 Mar 17. Epub 2018 Mar 17.
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
    Objectives: To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA). Read More

    Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study.
    Ann Rheum Dis 2018 Mar 13. Epub 2018 Mar 13.
    UMR 1027, INSERM, University of Toulouse, Toulouse, France.
    Objectives: To assess the efficacy and the safety of biologics in a cohort of patients with relapsing polychondritis (RP).

    Methods: We conducted a French multicentre retrospective cohort study including patients treated with biologics for RP. Efficacy outcomes were clinical response (partial or complete) and complete response during the first 6 months of exposure, plus daily corticosteroid dose at 6 months. Read More

    Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints-an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force.
    Ann Rheum Dis 2018 Mar 13. Epub 2018 Mar 13.
    Rheumatology Unit, Università di Torino, Torino, Italy.
    Objectives: To assess the reliability of the OMERACT ultrasound (US) definitions for the identification of calcium pyrophosphate deposition disease (CPPD) at the metacarpal-phalangeal, triangular fibrocartilage of the wrist (TFC), acromioclavicular (AC) and hip joints.

    Methods: A web-based exercise and subsequent patient-based exercise were carried out. A panel of 30 OMERACT members, participated at the web-based exercise by evaluating twice a set of US images for the presence/absence of CPPD. Read More

    Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
    Ann Rheum Dis 2018 Mar 10. Epub 2018 Mar 10.
    Rheumatology Associates, UT Southwestern Medical Center, Dallas, Texas, USA.
    A European League Against Rheumatism-American College of Rheumatology working group consisting of practising and academic rheumatologists, a rheumatology researcher and a patient representative created a succinct general statement describing rheumatic and musculoskeletal diseases (RMDs) in adults and children in language that can be used in conversations with the lay public, media, healthcare providers and other stakeholders. Based on the literature review, several elements were deemed important for inclusion in the description of RMDs. First, RMDs encompass many different diseases that can affect individuals at any age, including children. Read More

    Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.
    Ann Rheum Dis 2018 Mar 10. Epub 2018 Mar 10.
    Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
    Objectives: The aim of this study was to assess the psychological well-being and to analyse factors associated with depressive symptoms in axial spondyloarthritis (axSpA).

    Methods: A stratified random sample of subjects with a diagnosis of axSpA (International Classification of Diseases, Tenth Revision, German Modification M45) was drawn from health insurance data in Germany. These persons received a postal questionnaire on disease-related, psychological and lifestyle factors as well as socioeconomic status. Read More

    Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
    Ann Rheum Dis 2018 Mar 7. Epub 2018 Mar 7.
    Boehringer Ingelheim, Ingelheim am Rhein, Germany.
    Objective: To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira.

    Methods: Patients with active rheumatoid arthritis on stable methotrexate were randomised to BI 695501 or Humira in a double-blind, parallel-group, equivalence study. At week 24, patients were rerandomised to continue BI 695501 or Humira, or switch from Humira to BI 695501. Read More

    Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis.
    Ann Rheum Dis 2018 Mar 7. Epub 2018 Mar 7.
    Department of Medical Sciences, Science for Life Laboratory, Rheumatology, Uppsala University, Uppsala, Sweden.
    Objectives: Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have increased risk of cardiovascular disease (CVD). We investigated whether single nucleotide polymorphisms (SNPs) at autoimmunity risk loci were associated with CVD in SLE and RA.

    Methods: Patients with SLE (n=1045) were genotyped using the 200K Immunochip SNP array (Illumina). Read More

    Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial.
    Ann Rheum Dis 2018 Mar 7. Epub 2018 Mar 7.
    Department of General Practice, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
    Objectives: Guidelines recommend intra-articular glucocorticoid injection in patients with painful hip osteoarthritis. However, intra-articular hip injection is an invasive procedure. The efficacy of systemic glucocorticoid treatment for pain reduction in hip osteoarthritis is unknown. Read More

    'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis.
    Ann Rheum Dis 2018 Mar 6. Epub 2018 Mar 6.
    Rheumatology Department, Ospedale S.Maria Nuova, Reggio Emilia, Italy.
    Objectives: Skin and joint involvement in psoriasis (PsO) and psoriatic arthritis (PsA) are thought to relate to the so-called Koebner response. Given that dactylitis is non-randomly distributed in the digits, this study tested the hypothesis that the accessory pulleys linked to the flexor tendons were thickened in PsA and thus exhibited koebnerisation.

    Methods: Ninety-six subjects (27 PsA, 27 rheumatoid arthritis (RA), 23 PsO and 19 healthy controls (HCs)) were enrolled. Read More

    Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.
    Ann Rheum Dis 2018 Mar 1. Epub 2018 Mar 1.
    University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada.
    Objectives: To assess the risk of preterm delivery and small-for-gestational-age (SGA) births in women with autoimmune diseases using biologics before or during pregnancy.

    Methods: Using population-based administrative data in British Columbia, Canada, women with one or more autoimmune diseases who had pregnancies between 1 January 2002 and 31 December 2012 were included. Exposure to biologics was defined as having at least one biologic prescription 3 months before or during pregnancy. Read More

    Are MRI-detected erosions specific for RA? A large explorative cross-sectional study.
    Ann Rheum Dis 2018 Feb 28. Epub 2018 Feb 28.
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
    Objectives: MRI is recommended in the diagnostic process of rheumatoid arthritis (RA) to detect joint damage early. MRI-detected erosions are also present in symptom-free controls, especially at older age. It is unclear if RA-specific MRI-detected erosions can be distinguished from 'physiological' erosions in symptom-free individuals. Read More

    Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
    Ann Rheum Dis 2018 Feb 26. Epub 2018 Feb 26.
    Janssen Research & Development, Spring House, Pennsylvania, USA.
    Objective: This randomised, double-blind, parallel-group, phase 3 study compared monotherapy with sirukumab, an anti-interleukin-6 cytokine monoclonal antibody, with adalimumab monotherapy in patients with rheumatoid arthritis (RA).

    Methods: Biologic-naïve patients with active RA who were inadequate responders or were intolerant to, or inappropriate for, methotrexate were randomised to subcutaneous sirukumab 100 mg every 2 weeks (n=187), sirukumab 50 mg every 4 weeks (n=186) or adalimumab 40 mg every 2 weeks (n=186). Primary endpoints at week 24 were change from baseline in Disease Activity Score in 28 joints (DAS28) using erythrocyte sedimentation rate (ESR) and proportion of patients achieving an American College of Rheumatology (ACR) 50 response; these endpoints were tested in sequential order. Read More

    TheSLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE.
    Ann Rheum Dis 2018 Feb 23. Epub 2018 Feb 23.
    Department of Medical Sciences, Rheumatology and Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
    Objectives: Genetic variants in the transcription factorare associated with increased susceptibility to systemic lupus erythematosus (SLE) and a more severe disease phenotype. This study aimed to clarify how the SLE-associated intronicrisk allele rs7574865[T] affects the function of immune cells in SLE.

    Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 52 genotyped patients with SLE. Read More

    Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis.
    Ann Rheum Dis 2018 Feb 23. Epub 2018 Feb 23.
    Institute of Immunology, Biomedical Sciences Research Center (BSRC), 'Alexander Fleming', Vari, Greece.
    Objectives: Patients with rheumatoid arthritis and spondyloarthritisshow higher mortality rates, mainly caused by cardiac comorbidities. The TghuTNF (Tg197) arthritis model develops tumour necrosis factor (TNF)-driven and mesenchymalsynovial fibroblast (SF)-dependent polyarthritis. Here, we investigate whether this model develops, similarly to human patients, comorbid heart pathology and explore cellular and molecular mechanisms linking arthritis to cardiac comorbidities. Read More

    Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures.
    Ann Rheum Dis 2018 Feb 23. Epub 2018 Feb 23.
    Friedrich Alexander University Erlangen-Nürnberg, Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany.
    Objectives: Bone loss is a well-established consequence of rheumatoid arthritis (RA). To date, bone disease in RA is exclusively characterised by bone density measurements, while the functional properties of bone in RA are undefined. This study aimed to define the impact of RA on the functional properties of bone, such as failure load and stiffness. Read More

    Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register.
    Ann Rheum Dis 2018 Feb 23. Epub 2018 Feb 23.
    Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
    Objective: To compare the 10-year outcome (disease activity, disability, mortality) of two cohorts of patients with inflammatory polyarthritis (IP) recruited 10 years apart.

    Methods: Patients with IP were recruited to the Norfolk Arthritis Register from 1990 to 1994 (cohort 1 (C1)) and from 2000 to 2004 (cohort 2 (C2)). Demographic and clinical data were collected at baseline and at years 1, 2, 3, 5, 7 and 10. Read More

    Sialendoscopy enhances salivary gland function in Sjögren's syndrome: a 6-month follow-up, randomised and controlled, single blind study.
    Ann Rheum Dis 2018 Feb 23. Epub 2018 Feb 23.
    Department of Oral and Maxillofacial Surgery and Oral Pathology, VU University Medical Center, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
    Objectives: To assess the effect of sialendoscopy of the major salivary glands on salivary flow and xerostomia in patients with Sjögren's syndrome (SS).

    Methods: Forty-nine patients with SS were randomly assigned to a control group (n=15) and two intervention groups: irrigation of the major glands with saline (n=16) or with saline followed by triamcinolone acetonide (TA) in saline (n=18). Unstimulated whole saliva flow (UWS), chewing-stimulated whole saliva flow (SWS), citric acid-stimulated parotid flow (SPF), Clinical Oral Dryness Score (CODS), Xerostomia Inventory (XI) score and the European League Against Rheumatism (EULAR) SS Patient-Reported Index (ESSPRI) were obtained 1 week (T0) before, and 1 (T1), 8 (T8), 16 (T16) and 24 (T24) weeks after sialendoscopy. Read More

    Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
    Ann Rheum Dis 2018 Feb 22. Epub 2018 Feb 22.
    AB2 Bio Ltd, EPFL Innovation Park, Lausanne, Switzerland.
    Objectives: Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD.

    Methods: In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Read More

    Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
    Ann Rheum Dis 2018 Feb 20. Epub 2018 Feb 20.
    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
    Objectives: Lipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs.

    Methods: Lipid data were analysed from phase II and III studies of 4 mg (n=997) and 2 mg (n=479) oral baricitinib administered once daily in patients with moderate-to-severe active RA. Lipoprotein particle size and number and GlycA were evaluated with nuclear magnetic resonance in one phase III study. Read More

    ffect of pregnancy on disease flares in patients with systemic lupus erythematosus.
    Ann Rheum Dis 2018 Feb 20. Epub 2018 Feb 20.
    Department of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
    Objective: Prior studies found conflicting results about whether lupus is likely to flare during or after pregnancy. Using a large cohort of pregnant and non-pregnant women with lupus, we estimated the effect of pregnancy on disease flares in systemic lupus erythematosus.

    Methods: Data were collected in the Hopkins Lupus Cohort 1987-2015. Read More

    Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.
    Ann Rheum Dis 2018 Feb 20. Epub 2018 Feb 20.
    Department of Biochemistry, University of Otago, Dunedin, New Zealand.
    Objectives: To provide estimates of the cumulative incidence of gout according to baseline serum urate.

    Methods: Using individual participant data from four publicly available cohorts (Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, and both the Original and Offspring cohorts of the Framingham Heart Study), the cumulative incidence of clinically evident gout was calculated according to baseline serum urate category. Cox proportional hazards modelling was used to evaluate the relation of baseline urate categories to risk of incident gout. Read More

    Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study.
    Ann Rheum Dis 2018 Feb 20. Epub 2018 Feb 20.
    Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
    Objectives: The aim of this study was to adapt the Systemic Sclerosis Quality of Life Questionnaire (SScQoL) into six European cultures and validate it as a common measure of quality of life in systemic sclerosis (SSc).

    Methods: This was a seven-country (Germany, France, Italy, Poland, Spain, Sweden and UK) cross-sectional study. A forward-backward translation process was used to adapt the English SScQoL into target languages. Read More

    Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Ann Rheum Dis 2018 Feb 16. Epub 2018 Feb 16.
    Department of Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
    Objectives: To determine the reasons of methotrexate (MTX) discontinuation, frequency of adverse events (AE) and whether the time in inactive disease before MTX withdrawal disease is associated with the risk of disease flare.

    Methods: Patients with juvenile idiopathic arthritis (JIA) beginning treatment with MTX were prospectively observed in the national JIA biologic register Biologika in der Kinderrheumatologie/Biologics in Paediatric Rheumatology and its follow-up register Juvenile arthritis Methotrexate/Biologics long-term Observation. Inactive disease was defined by a clinical Juvenile Arthritis Disease Activity Score ≤1, flare after MTX discontinuation by reoccurrence of at least moderate disease activity or restart of treatment with a disease-modifying antirheumatic drug . Read More

    1 OF 289